Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(1):408-412. Published online 2018 May 23 DOI: https://doi.org/10.4143/crt.2018.138
|
Citations to this article as recorded by
Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients
Hyunjong Lee, Sujin Seo, Sungho Won, Woong-Yang Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
Scientific Reports.2023;[Epub] CrossRef Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(1): 188645. CrossRef Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
Rashidi Dzul Keflee, Kok Hoong Leong, Satoshi Ogawa, Jerome Bignon, Mun Chiang Chan, Kin Weng Kong
Biochemical Pharmacology.2022; 205: 115262. CrossRef Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer
Zhen Wu, Wei Zhao, Zhen Yang, Yue Ming Wang, Yu Dai, Liang-An Chen
Cancer Management and Research.2021; Volume 13: 2025. CrossRef Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
Hong-Shuai Li, Guang-Jian Yang, Yan Wang
Frontiers in Oncology.2021;[Epub] CrossRef Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C. Heukamp, Markus Falk
Cancers.2021; 13(12): 2861. CrossRef Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
BMB Reports.2021; 54(7): 386. CrossRef Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh
Journal of Medicinal Chemistry.2020; 63(1): 40. CrossRef Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
Gahyun Kim, Jinho Kim, Hongui Cha, Woong-Yang Park, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
Scientific Reports.2020;[Epub] CrossRef Afatinib/gefitinib/osimertinib
Reactions Weekly.2019; 1741(1): 16. CrossRef Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yunpeng Liu
BMC Cancer.2019;[Epub] CrossRef Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
Rashmi R. Shah, Devron R. Shah
Drug Safety.2019; 42(2): 181. CrossRef A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC
Yuanhao Lv, Tingting Du, Ming Ji, Chunyang Wang, Songwen Lin, Nina Xue, Jing Jin, Heng Xu, Xiaoguang Chen
Journal of Drug Targeting.2018; : 1. CrossRef
|